论文部分内容阅读
目的评价胺碘酮心律平治疗初发心房颤动的有效性、安全性及相关因素。方法回顾性分析83例初发心房颤动患者,分为胺碘酮心律平治疗组及对照组,1周内转复为窦性心律并维持24h为有效。结果治疗组总有效率69.2%,其中胺碘酮组73.9%,心律平组62.5%。对照组总有效率45.5%。治疗组平均住院时间(6.44±3.22)d,明显短于对照组(10.86±4.71)d。无论胺碘酮治疗组,还是心律平治疗组,均未发生严重的毒副作用。结论胺碘酮心律平治疗初发心房颤安全有效,同时还可缩短住院时间。
Objective To evaluate the efficacy, safety and related factors of amiodarone and cardiac rhythm in the treatment of primary atrial fibrillation. Methods A retrospective analysis of 83 patients with newly diagnosed atrial fibrillation was divided into amiodarone and control group. After 1 week, the patients were converted to sinus rhythm and maintained for 24h. Results The total effective rate was 69.2% in the treatment group, including 73.9% in the amiodarone group and 62.5% in the heart rhythm group. The control group, the total efficiency of 45.5%. The mean length of stay in the treatment group (6.44 ± 3.22) d was significantly shorter than that in the control group (10.86 ± 4.71) d. Regardless of amiodarone treatment group, or heart rhythm treatment group, no serious side effects. Conclusions Amiodarone and cardioversion are safe and effective in the treatment of first-episode atrial fibrillation, and meanwhile, hospitalization time can be shortened.